Tetraphase Pharmaceuticals

Biopharma takeovers show quantity, if not quality

Second-quarter deal values plummeted as Covid-19 spread and the prices of target companies spiralled.

Tetraphase’s love quadrangle sees three bald men fight over a comb

February 14, 2018

Intravenous inferiority makes it two failures for Tetraphase

July 14, 2017

Upcoming events – Zogenix to get Dravet data while Tetraphase concentrates on IV

October 06, 2015

Among smaller biopharmas, US groups take a back seat

September 21, 2015

ICAAC – Merck & Co scores with non-antibiotic antibacterial

September 09, 2015

End of an era for Tetraphase

June 26, 2015

Upcoming events: UniQure looks to prove gene therapy and crunch time for Tetraphase’s lead antibiotic

January 06, 2014

Fast times in biotech push IPO count to new highs

July 10, 2013

Floats rise out of the biotech bubble at last

April 03, 2013

IPO numbers stall as 2013 gets under way